MedTrace Logo

Prophylactic Antimalarial Activity of DB289 in Volunteers

NCT00408369 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2008-01-29

No results posted yet for this study

Summary

To evaluate the prophylactic activity of orally administered DB289 against Plasmodium falciparum in non-immune healthy volunteers who are challenged by the bite of five P. falciparum-infected Anopheles stephensi mosquitoes

Conditions

  • Prophylactic Activity Against Malaria

Interventions

DRUG

DB289

Sponsors & Collaborators

  • Immtech Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Theresa A. Shapiro, MD, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408369 on ClinicalTrials.gov